University of Birmingham Featured PhD Programmes
University of Huddersfield Featured PhD Programmes
University of Liverpool Featured PhD Programmes
Newcastle University Featured PhD Programmes
University of Leeds Featured PhD Programmes

Modelling of functional and tumour heterogeneity in human AML arisen from different cells-of-origin

This project is no longer listed on FindAPhD.com and may not be available.

Click here to search FindAPhD.com for PhD studentship opportunities
  • Full or part time
    Dr E So
    Dr A Thrasher
  • Application Deadline
    No more applications being accepted
  • Funded PhD Project (European/UK Students Only)
    Funded PhD Project (European/UK Students Only)

Project Description

This 4-year PhD studentship is offered by the Cancer Research UK City of London Centre

Acute myeloid leukemia (AML) together with acute lymphoid leukemia (ALL) account for about 1/3 of all paediatric cancers. In contrast to childhood ALL, which has a relatively favourable prognosis, AML has a much poorer projection and is one of the deadliest cancers. AML maintained by a small fraction of cancer stem cells is frequently initiated and driven by mutations affecting transcriptional and epigenetic machinery[1]. While hematopoietic stem cells (HSCs) have been traditionally viewed as the origins of human leukemia, we and others have previously shown that mutated transcription factors can also confer self-renewal properties to otherwise short-lived myeloid progenitors to initiate AML in mouse models[2]. Importantly, these genetically and immunophenotypically identical AML exhibit different biology and responses to treatments, revealing an additional level of tumour heterogeneity originating from their cells-of-origin[3]. Although most of the current evidence and literature are based on mouse cell models, we recently demonstrate for the first time that both human HSCs and myeloid progenitors can indeed be transformed by MLL-fusions to induce phenotypically indistinguishable AML commonly found in both childhood and adult leukemia patients, confirming the clinical relevance of cancer cell heterogeneity arising from their cells-of-origin in genetically and immunophenotypically homogeneous populations.

In this PhD project, we seek to provide new insights into this issue by using adeno-associated viral (AAVs) vectors in combination with CRISPR-CAS9 genome editing approach to recreate some of the most commonly AML mutations in human HSCs and early progenitors. Establishing these models will enable us to prospectively identify the potential origins of the AML stem cells and characterize the transcriptional and epigenetic landscapes of the transformed cells leading to the observed cellular heterogeneity. This cross-disciplinary project will take the full advantage of the expertise and support of complementing research groups within the newly form City of London CRUK Center. The team includes Prof. So’s group in KCL who pioneered modelling human AML and characterizing their aberrant epigenetic networks[1-3]; Prof. Thrasher’s group in UCL who has a long standing interest and track record in applying genome editing technologies in human haematopoietic stem and progenitor cells[4]; Dr Liswoski’s group in Children Medical Research Institute (CMRI) Sydney/UCL who specializes in developing novel AAV vectors for effective gene transfer and genome editing in HSCs [5]; and Prof. Ciccarelli’s group In the Crick/KCL who is an expert in cancer genomics and bioinformatics. The student is expected to be exposed and receive training in all these areas during the PhD. The first-year rotations will include studies in So’s group, Thrasher’s group and Ciccarelli’s group. In addition, the student will also have an opportunity to receive training on novel vector development at CMRI. The candidate should have a minimum of BSc but preferably a MSc in one of these subjects (Biomedical Sciences; Biological Sciences; Biotechnology; Biochemistry; or related subjects). Prior work experiences in a research lab or industry will be considered favourably.

Suitable candidates for this project will have degree in Biomedical / Biological Sciences or related subjects.

Potential research placements

1. Leukemia and Stem Cell Biology: training on cancer biology and epigenetics. Prof So, King’s College London.
2. Molecular and Cellular Immunology: training on gene transfer/genome editing technology in HSPCs and molecular immunology. Prof. Thrasher, UCL.
3. Cancer Bioinformatics: bio-informatic and computational training on cancer genetics and epigenetics. Prof Ciccarelli, the Crick.


Talented and motivated students passionate about doing research are invited to apply for this PhD position. The successful applicant will join the CRUK CoL Centre PhD Programme in September 2019 and will register for their PhD at their primary supervisor’s University.
Applicants should hold or expect to gain a first/upper second-class honours degree or equivalent in a relevant subject and have appropriate research experience as part of, or outside of, a university degree course and/or a Masters degree in a relevant subject.

APPLICATIONS MUST BE MADE ONLINE VIA OUR WEBSITE (ACCESSIBLE VIA THE ‘APPLY NOW’ LINK ABOVE) BY 12:00 (NOON) 19 MARCH 2019. APPLICATIONS WILL NOT BE ACCEPTED IN ANY OTHER FORMAT.

Funding Notes

Successful candidates will receive a £21,000 tax-free student stipend (living allowance) per year for 4 years plus payment of university tuition fees. Non-EU candidates are not eligible to apply.

References

1. Zeisig BB et al. SnapShot: Acute myeloid leukemia. Cancer Cell, 2012; 22(5): p. 698-698 e1.
2. So CW et al. MLL-GAS7 transforms multipotent hematopoietic progenitors and induces mixed lineage leukemias in mice. Cancer Cell, 2003; 3(2): p. 161-71.
Siriboonpiputtana T et al. Transcriptional memory of cells of origin overrides beta-catenin requirement of MLL cancer stem cells. EMBO J, 2017; 36(21): p. 3139-3155.
3. Booth C, Gaspar HB, Thrasher AJ. Treating Immunodeficiency through HSC Gene Therapy. Trends Mol Med, 2016; 22(4): p. 317-327.
4. Lisowski L, Tay SS, Alexander IE. Adeno-associated virus serotypes for gene therapeutics. Curr Opin Pharmacol, 2015; 24: p. 59-67.



FindAPhD. Copyright 2005-2019
All rights reserved.